24/7 Market News- Adial Pharmaceuticals AD04 Advances to Second Cohort in Pharmacokinetics Study for the Treatment of AUD
DENVER, Colo., Jul 23, 2024 (247marketnews.com)- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) stated the progression to the second cohort in the pharmacokinetics study of AD04, following the successful completion of the first cohort of the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD). Topline results from both cohorts are expected to be announced later this year.
Adial’s President and CEO, Cary Claiborne, stated, “We are pleased with the progress of our pharmacokinetics study of AD04. The successful completion of the first cohort allows us to advance to the second cohort as planned, staying on track with our projected timeline. The results from both cohorts will offer invaluable insights that are critical for the design of our upcoming Phase 3 Clinical Trial. We anticipate engaging with the FDA following receipt of the topline data from this study and seek their feedback on the overall design of our Phase 3 program.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (ADIL)
- Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
- Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting
- Today’s Top Performers: MoBot’s Market Review 07/29/25 08:00 AM
- Today’s Top Performers: MoBot’s Market Review 07/28/25 04:00 PM
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/28/25 11:00 AM